EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Nicholas Turner iD, Cristina Saura iD, Philippe Aftimos iD, Evelyn van den Tweel iD, Mayke Oesterholt iD, Norbert Koper, Marco Colleoni iD, Emilie Kaczmarek, Kevin Punie iD, Xinni Song, Anne Armstrong, Giulia Bianchi und 8 weitere

Journal of Clinical Oncology · 10.02.2025 · 43 (5) · 513-523

DOI: 10.1200/jco.24.00529 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2025. Verfasst von Nicholas Turner und 19 weiteren Autor:innen. Beteiligte Einrichtung: Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Human epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently exists beyond second line. Trastuzumab duocarmazine (T-Duo) is a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies of heavily pretreated patients with HER2+/HER2-low breast cancer. METHODS In this open-label, randomized, phase III trial, T-Duo was compared with physician's choice (PC) in patients with unresectable locally advanced/metastatic HER2+ breast cancer with progression during/after ≥2 HER2-targeted therapies or after trastuzumab emtansine (T-DM1). The primary endpoint was progression-free survival (PFS) by blinded independent central review. RESULTS In total, 437 patients were randomly assigned 2:1 to T-Duo (n = 291) or PC (n = 146). The median age was 56.0 years (range, 24-86); most patients (93.6%) had metastatic disease. The median time from diagnosis of metastatic disease to trial entry was 3.5 years; the median number of prior HER2-targeted therapies in metastatic setting was three. The median PFS was 7.0 months (95% CI, 5.4 to 7.2) with T-Duo versus 4.9 months (95% CI, 4.0 to 5.5; hazard ratio [HR], 0.64 [95% CI, 0.49 to 0.84]; P = .002) with PC. PFS benefit was maintained across most predefined subgroups. The median overall survival (first analysis) was 20.4 (T-Duo) versus 16.3 months (PC; HR, 0.83 [95% CI, 0.62 to 1.09]; P = .153). Objective response rate was 27.8% (T-Duo) versus 29.5% (PC); other efficacy end points—clinical benefit rate, duration of response, and reduction in target lesion measurement—tended to favor T-Duo. Grade ≥3 treatment-emergent adverse events occurred in 52.8% (T-Duo) versus 48.2% (PC). CONCLUSION Treatment with T-Duo was manageable, but tolerability was affected by prevalent ocular toxicity, leading to a higher discontinuation rate in the T-Duo arm. T-Duo significantly reduced the risk of progression in patients with advanced HER2+ breast cancer who have progressed during/after ≥2 HER2-targeted therapies or after T-DM1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedAdultAgedProgression-Free SurvivalAged, 80 and overNeoplasm Metastasis

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Agents, ImmunologicalERBB2 protein, human

Autor:innen und Institutionen

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.
  • Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
  • Byondis B.V., Nijmegen, the Netherlands.
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy.
  • Medical Oncology Department, Centre Oscar Lambret, Lille, France.

ORCID-Profile: Nicholas Turner, Cristina Saura, Philippe Aftimos, Evelyn van den Tweel, Mayke Oesterholt, Marco Colleoni, Kevin Punie, Agostina Stradella, Sylvain Ladoire, Joline Si Jing Lim, Tira J Tan

Zitieren

APA

Turner, N., Saura, C., Aftimos, P., van den Tweel, E., Oesterholt, M., Koper, N., Colleoni, M., Kaczmarek, E., Punie, K., Song, X., Armstrong, A., Bianchi, G., Stradella, A., Ladoire, S., Lim, J. S. J., Quenel-Tueux, N., Tan, T. J., Escrivá-de-Romaní, S., O'Shaughnessy, J., & TULIP Trial Investigators (2025). Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). Journal of Clinical Oncology, 43(5), 513-523. https://doi.org/10.1200/jco.24.00529

Vancouver

Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, et al. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). Journal of Clinical Oncology. 2025;43(5):513-523. doi:10.1200/jco.24.00529

BibTeX
@article{Turner2025,
  author = {Turner, Nicholas and Saura, Cristina and Aftimos, Philippe and van den Tweel, Evelyn and Oesterholt, Mayke and Koper, Norbert and Colleoni, Marco and Kaczmarek, Emilie and Punie, Kevin and Song, Xinni and Armstrong, Anne and Bianchi, Giulia and Stradella, Agostina and Ladoire, Sylvain and Lim, Joline Si Jing and Quenel-Tueux, Nathalie and Tan, Tira J and Escrivá-de-Romaní, Santiago and O'Shaughnessy, Joyce and TULIP Trial Investigators, TULIP Trial Investigators},
  title = {Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {5},
  pages = {513--523},
  doi = {10.1200/jco.24.00529}
}
Kostenlos starten →